The majority of the cohort had a typical heart failure medication; 528 (90%) patients were treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers, 545 (93%) received β-blockers, diuretics were used in 432 (74%) patients, mineralocorticoid receptor antagonists in 298 (51%) patients, and digitalis glycosides in 183 (31%) patients. The gene discussed is NR3C2; the disease is heart failure.